Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Joel W. Hay, PhD

    TitleProfessor of Pharmaceutical Economics & Policy
    SchoolSchool of Pharmacy
    DepartmentPharmacology and Pharmaceutical Sciences
    AddressVPD 214-L
    Off Campus
    Los Angeles California 90089-3333
    Phone+1 818 338 5433
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Joel W. Hay is Professor and Founding Chair in the Department of Pharmaceutical Economics and Policy in the School of Pharmacy, with a joint appointment in the Department of Economics and in the Leonard Schaeffer Center for Health Policy and Economics at the University of Southern California. He also serves as the USC Project Coordinator for the Rand Evidence-Based Medicine Practice Centers of Southern California funded by the US Agency for Health Research and Quality, and Co-Investigator at the USC Alzheimer Research Center funded by the California Dept. of Health Services. He is a Health Economics Research Scholar at the UCLA Center for Vaccine Research. He is a founding Executive Board member of the American Society for Health Economics and of the International Society for Pharmaceutical Economics and Outcomes Research.

      His previous positions include: Senior Research Fellow, the Hoover Institution, Stanford University (1985-1992); Senior Policy Analyst, Project HOPE (1983-1985); Asst. Professor, Dept. of Behavioral Sciences and Community Health, and Dept. of Economics, University of Connecticut (1980-1984); and Asst. Research Professor, University of Southern California (1978-1980). . He received his B.A. summa cum laude from Amherst College in 1974 and his M.A. (1975), M. Ph. (1976) and Ph.D. in economics (1980) from Yale University.

      Dr. Hay has authored or coauthored over 400 peer-reviewed scientific articles, abstracts, editorials and reports in the fields of pharmaceutical economics, health economics, outcomes research, disease management, statistics, econometrics, epidemiology and health care in journals including more than 160 peer-reviewed scientific articles in journals such as: American Journal of Cardiology, American Journal of Health-Systems Pharmacy, American Journal of Managed Care, American Journal of Public Heath, Archives of Neurology, Haemophilia, Health Care Financing Review, Health Policy, JAMA, Journal of AIDS, Journal of the American Geriatrics Society, Journal of Business & Economic Statistics, Journal of Clinical Gastroenterology, Journal of Health Economics, Journal of Health Politics, Policy and Law, Journal of Human Resources, Journal of the Royal Statistical Association, Medical Care, Pediatrics and Value in Health.

      Dr. Hay has served as a consultant to U.S. Centers for Medicare and Medicaid Services, U.S. Agency for Healthcare Research and Quality, U.S. Centers for Disease Control and Prevention, U.S. Public Health Service, U.S. Food and Drug Administration, U.S. Environmental Protection Agency, Government of Hungary, Hong Kong Centre for Economic Research, Hong Kong Medical Executives Association, World Bank, California AIDS Commission, California Medi-Cal Drug Advisory Board, County of San Diego Medically Indigent Adult program, and County of Sacramento Homeless Program. Dr. Hay has also written numerous health-related editorials published in papers such as Los Angeles Times, New York Times, Wall Street Journal, San Francisco Chronicle, San Diego Union, Sacramento Bee and Newsday.

      Dr. Hay has served as a Member of the Expert Advisory Panel on Drug Utilization Review, United States Pharmacopeial Convention; an Executive Committee member for the federally-sponsored Southern California Evidence-Based Medicine Practice Center; and a member of the JAMA Web Site HIV/AIDS Editorial Review Panel. Dr. Hay is a founding member of the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research. He has recently completed a study of hospital and pharmaceutical costs for the national Blue Cross Blue Shield Association (http://bcbshealthissues.com/costpressconf/materials.vtml). This report has been discussed in several national media, including NPR, CSPAN, USA Today, US News and World Report and others.

      Joel Hay was Founding Editor-in-Chief of Value in Health the peer-reviewed scientific journal of the International Society for Pharmacoeconomics and Outcomes Research until 2003. This journal, started in 1998, became Medline-listed in 2002. In its first impact factor, Value in Health was ranked #1 in two categories for the year 2004, by the ISI Journal Citation Reports® (JCR) with an impact factor of 3.657. Value in Health led all other journals listed both in the Health Care Sciences and Services category in the JCR Science Edition and in the Health Policy & Services category in the JCR Social Sciences Edition.


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Carlson M, Vigen CL, Rubayi S, Blanche EI, Blanchard J, Atkins M, Bates-Jensen B, Garber SL, Pyatak EA, Diaz J, Florindez LI, Hay J, Mallinson T, Unger JB, Azen SP, Scott M, Cogan A, Clark F. Lifestyle intervention for adults with spinal cord injury: Results of the USC-RLANRC Pressure Ulcer Prevention Study. J Spinal Cord Med. 2017 Apr 17; 1-18. PMID: 28414254.
        View in: PubMed
      2. Gong CL, Hay J, Meeker D, Doctor JN. Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. BMJ Open. 2016 Sep 22; 6(9):e012739. PMID: 27660322.
        View in: PubMed
      3. Drabo EF, Hay J, Vardavas R, Wagner ZR, Sood N. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Clin Infect Dis. 2016 Dec 01; 63(11):1495-1504. PMID: 27558571.
        View in: PubMed
      4. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, Knight TK, Hay J, Doctor JN. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial. JAMA. 2016 Feb 09; 315(6):562-70. PMID: 26864410.
        View in: PubMed
      5. Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay J. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. J Manag Care Spec Pharm. 2016 Feb; 22(2):149-57. PMID: 27015254.
        View in: PubMed
      6. Chaugule SS, Hay J, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015; 9:1623-30. PMID: 26635471; PMCID: PMC4646600.
      7. Chen CX, Hay J. Promise of Precision Medicine. JAMA. 2015 Oct 27; 314(16):1752. PMID: 26505605.
        View in: PubMed
      8. Cheetham TC, Niu F, Chiang K, Yuan Y, Kalsekar A, Hechter R, Hay J, Nyberg L. Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm. 2015 Aug; 21(8):641-7. PMID: 26233536.
        View in: PubMed
      9. Thompson CA, Hay J. Marijuana use in models for health outcomes. Am J Med. 2015 Mar; 128(3):e23. PMID: 25707892.
        View in: PubMed
      10. Thompson CA, Hay J. Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. Ann Epidemiol. 2015 Jul; 25(7):486-91. PMID: 25743435.
        View in: PubMed
      11. Grosse SD, Chaugule SS, Hay J. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr; 15(2):267-83. PMID: 25585817; PMCID: PMC4513931.
      12. Zhang X, Hay J, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-ß1a in relapsing-remitting multiple sclerosis. CNS Drugs. 2015 Jan; 29(1):71-81. PMID: 25326785.
        View in: PubMed
      13. Chen CX, Hay J. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol. 2015 Feb 15; 181:417-24. PMID: 25569270.
        View in: PubMed
      14. Messali A, Villacorta R, Hay J. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec; 32(12):1201-12. PMID: 25085219.
        View in: PubMed
      15. Gong CL, Hay J. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014 Oct; 12(10):1417-25. PMID: 25313181.
        View in: PubMed
      16. Villacorta R, Hay J, Messali A. Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2014 Aug; 14(4):545-58. PMID: 24820676.
        View in: PubMed
      17. Clark F, Pyatak EA, Carlson M, Blanche EI, Vigen C, Hay J, Mallinson T, Blanchard J, Unger JB, Garber SL, Diaz J, Florindez LI, Atkins M, Rubayi S, Azen SP. Implementing trials of complex interventions in community settings: the USC-Rancho Los Amigos pressure ulcer prevention study (PUPS). Clin Trials. 2014 Apr; 11(2):218-29. PMID: 24577972; PMCID: PMC3972348.
      18. Mehta DA, Hay J. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecol Oncol. 2014 Mar; 132(3):677-83. PMID: 24463160.
        View in: PubMed
      19. Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay J. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One. 2013; 8(11):e80639. PMID: 24260441; PMCID: PMC3832449.
      20. Villacorta R, Hay J, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013 Sep; 31(9):823-39. PMID: 23975739.
        View in: PubMed
      21. Ganapathy V, Hay J, Kim JH, Lee ML, Rechtman DJ. Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr. 2013 Aug 20; 13:127. PMID: 23962093; PMCID: PMC3765805.
      22. Messali A, Hay J, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013 Nov; 15(11):1532-42. PMID: 23935155; PMCID: PMC3813411.
      23. Hay J. Effects of medicaid on clinical outcomes. N Engl J Med. 2013 Aug 08; 369(6):581-2. PMID: 23924020.
        View in: PubMed
      24. Bollu V, Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay J. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ. 2013 Aug; 16(8):1082-8. PMID: 23777224.
        View in: PubMed
      25. Hay J, Chaugule SC, Young G. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Haemophilia. 2013 Sep; 19(5):711-9. PMID: 23672765.
        View in: PubMed
      26. Ding Y, Yeh SH, Mink CA, Zangwill KM, Allred NJ, Hay J. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine. 2013 May 24; 31(22):2558-64. PMID: 23583811.
        View in: PubMed
      27. Hay J. Costs and benefits of male circumcision. JAMA Pediatr. 2013 Feb; 167(2):198. PMID: 23381456.
        View in: PubMed
      28. Hay J. What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med. 2012 Oct 22; 172(19):1521-2; author reply 1522-3. PMID: 23090194.
        View in: PubMed
      29. Kawatkar AA, Hay J, Stohl W, Nichol MB. Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. PMID: 22718267.
        View in: PubMed
      30. Suh HS, Hay J, Johnson KA, Doctor JN. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf. 2012 May; 21(5):470-84. PMID: 22461130.
        View in: PubMed
      31. Ding Y, Zangwill KM, Hay J, Allred NJ, Yeh SH. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):306-14. PMID: 22270282.
        View in: PubMed
      32. Zhou ZY, Hay J. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther. 2012 Feb; 34(2):434-45. PMID: 22285208.
        View in: PubMed
      33. Hay J, Katon WJ, Ell K, Lee PJ, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012 Mar-Apr; 15(2):249-54. PMID: 22433755; PMCID: PMC3310347.
      34. Ganapathy V, Hay J, Kim JH. Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med. 2012 Feb; 7(1):29-37. PMID: 21718117.
        View in: PubMed
      35. Hay J, Zhou ZY. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. J Med Econ. 2011; 14(4):516-25. PMID: 21699366.
        View in: PubMed
      36. Hay J, Zhou ZY. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia. 2011 Sep; 17(5):e969-74. PMID: 21649802.
        View in: PubMed
      37. Clark F, Jackson J, Carlson M, Chou CP, Cherry BJ, Jordan-Marsh M, Knight BG, Mandel D, Blanchard J, Granger DA, Wilcox RR, Lai MY, White B, Hay J, Lam C, Marterella A, Azen SP. Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. J Epidemiol Community Health. 2012 Sep; 66(9):782-90. PMID: 21636614; PMCID: PMC3412049.
      38. Mark TL, Joish VN, Hay J, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry. 2011 Mar; 19(3):211-21. PMID: 21425504.
        View in: PubMed
      39. Dwight-Johnson M, Lagomasino IT, Hay J, Zhang L, Tang L, Green JM, Duan N. Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos. Psychiatr Serv. 2010 Nov; 61(11):1112-8. PMID: 21041350.
        View in: PubMed
      40. Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay J. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent. 2010 Nov-Dec; 58(6):484-92; quiz 493-4. PMID: 21062718.
        View in: PubMed
      41. Hay J, Jhaveri M, Tangirala M, Kaliner M. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009 Nov-Dec; 30(6):634-42. PMID: 20031009.
        View in: PubMed
      42. Hay J, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health. 2010 Jan-Feb; 13(1):3-7. PMID: 19874571.
        View in: PubMed
      43. Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay J, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health. 2010 Jan-Feb; 13(1):28-33. PMID: 19883403.
        View in: PubMed
      44. Mansley EC, Carroll NV, Chen KS, Shah ND, Piech CT, Hay J, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health. 2010 Jan-Feb; 13(1):14-7. PMID: 19883404.
        View in: PubMed
      45. Mycka JM, Dellamano R, Kolassa EM, Wonder M, Ghosh S, Hay J, Smeeding J. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health. 2010 Jan-Feb; 13(1):25-7. PMID: 19883402.
        View in: PubMed
      46. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay J, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health. 2010 Jan-Feb; 13(1):8-13. PMID: 19883405.
        View in: PubMed
      47. Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay J, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health. 2010 Jan-Feb; 13(1):18-24. PMID: 19807903.
        View in: PubMed
      48. Hay J, Zhou ZY. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2010 Mar; 16(2):366-8; discussion 369-71. PMID: 19811544.
        View in: PubMed
      49. Hay J, Kaliner MA. Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. Curr Med Res Opin. 2009 Jun; 25(6):1421-31. PMID: 19422280.
        View in: PubMed
      50. Le QA, Hay J. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009 Feb 01; 115(3):489-98. PMID: 19117341.
        View in: PubMed
      51. Gu NY, Gai Y, Hay J. The effect of patient satisfaction with pharmacist consultation on medication adherence: an instrumental variable approach. Pharm Pract (Granada). 2008 Oct; 6(4):201-10. PMID: 25157295; PMCID: PMC4141731.
      52. Hay J. Using pharmacoeconomics to value pharmacotherapy. Clin Pharmacol Ther. 2008 Aug; 84(2):197-200. PMID: 18679182.
        View in: PubMed
      53. Hay J, Lawler E, Yucel K, Guo A, Balzer T, Gaziano JM, Scranton RE. Cost impact of diagnostic imaging for lower extremity peripheral vascular occlusive disease. Value Health. 2009 Mar-Apr; 12(2):262-6. PMID: 18657093.
        View in: PubMed
      54. Gabel JR, Fahlman C, Kang R, Wozniak G, Kletke P, Hay J. Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood). 2008 May-Jun; 27(3):w165-74. PMID: 18349040.
        View in: PubMed
      55. Zeiger RS, Hay J, Contreras R, Chen W, Quinn VP, Seal B, Schatz M. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol. 2008 Apr; 121(4):885-92.e5. PMID: 18313133.
        View in: PubMed
      56. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008 Mar; 11 Suppl 1:S11-22. PMID: 18387054.
        View in: PubMed
      57. Scranton RE, Dhingra R, Lawler EV, Yucel K, Guo A, Chittamooru SP, Gagnon DR, Hay J, Gaziano JM. A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol. 2008; 17(2):78-82. PMID: 22477392; PMCID: PMC2728421.
      58. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008 Jan-Feb; 14(1):21-33. PMID: 18240879.
        View in: PubMed
      59. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay J. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother. 2007 Nov; 8(16):2775-87. PMID: 17956198.
        View in: PubMed
      60. Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, Hay J, Yancy CW, Fonarow GC. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J. 2007 Aug; 154(2):267-77. PMID: 17643575.
        View in: PubMed
      61. Hay J. Where's the value in health care? Value Health. 2006 May-Jun; 9(3):141-3. PMID: 16689706.
        View in: PubMed
      62. Stephens JM, Botteman MF, Hay J. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006 Mar; 12(2):130-42. PMID: 16515371.
        View in: PubMed
      63. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics. 2006; 24(12):1221-32. PMID: 17129076.
        View in: PubMed
      64. Hay J. Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy. 2006; 5(4):269-70; author reply 270-2. PMID: 17249843.
        View in: PubMed
      65. Hay J, Leahy M. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program. Value Health. 2005 Jul-Aug; 8(4):506-16. PMID: 16091028.
        View in: PubMed
      66. Hay J, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005 Jun; 24(6 Suppl):S127-33. PMID: 15931140.
        View in: PubMed
      67. Hay J. Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm. 2005 May; 11(4):344-8. PMID: 15871646.
        View in: PubMed
      68. Hay J. The cost effectiveness of cardiovascular medicines. Curr Atheroscler Rep. 2005 Mar; 7(2):79-80. PMID: 15727719.
        View in: PubMed
      69. Hay J, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005; 23(2):133-41. PMID: 15748088.
        View in: PubMed
      70. Zhang L, Hay J. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs. 2005; 19(7):635-42. PMID: 15984898.
        View in: PubMed
      71. Forrest S, Goetghebeur MM, Hay J. Medicare coverage and reimbursement of outpatient prescription drugs in the US: history, recent changes and outlook for the future. Appl Health Econ Health Policy. 2005; 4(1):9-14. PMID: 16076234.
        View in: PubMed
      72. Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res. 2004 Dec; 4(6):625-34. PMID: 19807536.
        View in: PubMed
      73. Hay J. Evaluation and review of pharmacoeconomic models. Expert Opin Pharmacother. 2004 Sep; 5(9):1867-80. PMID: 15330725.
        View in: PubMed
      74. Dwight-Johnson M, Lagomasino IT, Aisenberg E, Hay J. Using conjoint analysis to assess depression treatment preferences among low-income Latinos. Psychiatr Serv. 2004 Aug; 55(8):934-6. PMID: 15292545.
        View in: PubMed
      75. Purdy KW, Hay J, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004 Jul 01; 39(1):20-8. PMID: 15206048.
        View in: PubMed
      76. Chen L, Hay J. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004 Mar; 18(2):161-70. PMID: 15162078.
        View in: PubMed
      77. Hay J. Evaluating the cost-effectiveness of statins. J Manag Care Pharm. 2004 Jan-Feb; 10(1):79-81. PMID: 14720107.
        View in: PubMed
      78. Etemad LR, Hay J. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health. 2003 Jul-Aug; 6(4):425-35. PMID: 12859583.
        View in: PubMed
      79. Hay J. Hospital cost drivers: an evaluation of 1998-2001 state-level data. Am J Manag Care. 2003 Jun; 9 Spec No 1:SP13-24. PMID: 12817612.
        View in: PubMed
      80. Goetghebeur MM, Forrest S, Hay J. Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care. 2003 Jun; 9 Spec No 1:SP3-12. PMID: 12817611.
        View in: PubMed
      81. Yuan Y, Hay J, McCombs JS. Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care. 2003 Jan; 9(1):45-56. PMID: 12549814.
        View in: PubMed
      82. Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay J. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003 Jan-Feb; 9(1):53-61. PMID: 14613362.
        View in: PubMed
      83. Chiou CF, Hay J, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003 Jan; 41(1):32-44. PMID: 12544542.
        View in: PubMed
      84. Hay J. Expensive conditions. Health Aff (Millwood). 2002 Nov-Dec; 21(6):271-2; author reply 272. PMID: 12442870.
        View in: PubMed
      85. Hay J, LaBree L, Luo R, Clark F, Carlson M, Mandel D, Zemke R, Jackson J, Azen SP. Cost-effectiveness of preventive occupational therapy for independent-living older adults. J Am Geriatr Soc. 2002 Aug; 50(8):1381-8. PMID: 12164994.
        View in: PubMed